Mass Tort brief
Pharma Logistics and Device Liability on Trial
From supply chain failures disrupting Israeli pharmacies to generic pricing deadlines, corporate liability is testing drugmakers and underwriters.
Mass Tort
A botched software migration that halted national drug deliveries cost Novolog ₪5M — establishing strict corporate liability for pharmaceutical logistics failures.
BackgroundNovolog is one of Israel's two dominant pharmaceutical distribution and cold-chain logistics contractors, handling wholesale supply from multinational drugmakers to institutional pharmacies and hospitals. A flawed migration to a new SAP enterprise system in early 2025 paralyzed its distribution warehouses.
- Novolog will pay ₪3.5 million directly to the statutory Fund for Distributing Class Action Relief to settle consumer claims without admitting legal liability.
- The company will distribute an additional ₪1.5 million in ₪300 patient treatment vouchers through the Israel Diabetes Association, Chaverim L'Refuah, and Kav LaChaim.
- The settlement resolves allegations that supply delays lasting from January to March 2025 left thousands of chronic patients without vital prescription therapies.
- Court approval was granted after external audits confirmed that Novolog stabilized its inventory management software and restored reliable deliveries.
Mass Tort
Fresh product liability filings in the Paragard IUD litigation keep legacy medical device risks alive for Teva — forcing it to manage ongoing courtroom exposure.
BackgroundTeva Pharmaceutical Industries developed and marketed the Paragard copper IUD before selling the product line to CooperSurgical in 2017 while retaining liability for prior manufacturing periods. Over 2,000 product liability claims have been consolidated in MDL 2974 before Judge Leigh Martin May in Atlanta.
- The newly docketed lawsuit, Labelle v. Teva Pharmaceuticals, alleges the manufacturer failed to warn physicians about embrittlement risks that cause device arms to break.
- Plaintiffs allege that broken copper fragments require invasive surgical procedures, causing internal organ lacerations and potential loss of reproductive fertility.
- The MDL court directed litigation leadership committees to finalize proposed consent orders to structure bellwether trials for remaining claims.
- Teva continues to defend against legacy product liability risks while managing extensive compliance and debt obligations under CEO Richard Francis.
Mass Tort
Direct Insurance settled class litigation challenging personal injury payout hurdles — forcing retail insurers to simplify claim approvals for accident victims.
BackgroundIDI Insurance, known as Direct Insurance, is a leading direct retail underwriter in Israel that sells vehicle, property, and personal accident policies without independent brokers. Consumer advocates have repeatedly challenged contractual policy clauses that restrict disbursements after accidents.
- The class action challenged policy terms where IDI conditioned personal accident benefit payouts on onerous administrative proof requirements.
- The proposed settlement filed with the Tel Aviv District Court establishes simplified documentation procedures and financial compensation for past claimants.
- The agreement remains subject to formal judicial approval following a statutory review period by the Capital Market, Insurance and Savings Authority.
- Insurance analysts expect the settlement to prompt rival Israeli retail underwriters to review and clarify exclusionary definitions within personal accident products.
Mass Tort
Taro Pharmaceuticals' $200M antitrust settlement window closes today — ending consumer claims over generic price fixing while state battles continue.
BackgroundHaifa-founded Taro Pharmaceuticals, acquired by Indian pharma giant Sun Pharma, was named alongside major global generic manufacturers in federal antitrust litigation in Philadelphia. The litigation accused drugmakers of coordinating generic drug price increases across the US market.
- The $200 million Taro resolution forms part of a broader $533 million end-payer settlement overseen by US District Judge Cynthia M. Rufe.
- Taro is simultaneously battling state attorneys general in Connecticut federal court, attempting to use the MDL settlement terms to block state enforcement claims.
- Institutional healthcare providers and retail purchasers who paid inflated prices for generic medications must submit valid claims before the midnight window closes.
- Antitrust compliance mandates resulting from the litigation continue to reshape commercial pricing strategies for Israeli-linked pharmaceutical manufacturers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
